Clear Harbor Asset Management LLC Has $372,000 Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Clear Harbor Asset Management LLC raised its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 19.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,322 shares of the company’s stock after buying an additional 694 shares during the period. Clear Harbor Asset Management LLC’s holdings in Novo Nordisk A/S were worth $372,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of NVO. Novare Capital Management LLC boosted its position in Novo Nordisk A/S by 3.2% during the third quarter. Novare Capital Management LLC now owns 2,727 shares of the company’s stock valued at $325,000 after purchasing an additional 85 shares during the last quarter. Rosenberg Matthew Hamilton lifted its holdings in shares of Novo Nordisk A/S by 2.5% during the 3rd quarter. Rosenberg Matthew Hamilton now owns 3,812 shares of the company’s stock valued at $454,000 after buying an additional 94 shares during the last quarter. Burns J W & Co. Inc. NY grew its stake in shares of Novo Nordisk A/S by 1.9% in the 3rd quarter. Burns J W & Co. Inc. NY now owns 5,430 shares of the company’s stock valued at $647,000 after buying an additional 100 shares in the last quarter. Spinnaker Trust increased its holdings in Novo Nordisk A/S by 1.1% in the third quarter. Spinnaker Trust now owns 9,615 shares of the company’s stock worth $1,145,000 after buying an additional 100 shares during the last quarter. Finally, Marco Investment Management LLC raised its position in Novo Nordisk A/S by 1.5% during the third quarter. Marco Investment Management LLC now owns 6,702 shares of the company’s stock valued at $798,000 after acquiring an additional 100 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on NVO. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BMO Capital Markets lowered their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Finally, StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $140.20.

Novo Nordisk A/S Stock Performance

NVO opened at $80.95 on Wednesday. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The stock’s 50 day moving average price is $97.15 and its two-hundred day moving average price is $116.47. The firm has a market capitalization of $363.25 billion, a P/E ratio of 26.20, a price-to-earnings-growth ratio of 0.84 and a beta of 0.45. Novo Nordisk A/S has a 12-month low of $78.17 and a 12-month high of $148.15.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.